132 related articles for article (PubMed ID: 1978329)
1. Correlation of the structure of the transmembrane domain of the neu oncogene-encoded p185 protein with its function.
Brandt-Rauf PW; Rackovsky S; Pincus MR
Proc Natl Acad Sci U S A; 1990 Nov; 87(21):8660-4. PubMed ID: 1978329
[TBL] [Abstract][Full Text] [Related]
2. Conformational changes induced by the transforming amino acid substitution in the transmembrane domain of the neu oncogene-encoded p185 protein.
Brandt-Rauf PW; Pincus MR; Chen JM
J Protein Chem; 1989 Dec; 8(6):749-56. PubMed ID: 2576207
[TBL] [Abstract][Full Text] [Related]
3. Conformation of the transmembrane domain of the c-erbB-2 oncogene-encoded protein in its monomeric and dimeric states.
Brandt-Rauf PW; Pincus MR; Monaco R
J Protein Chem; 1995 Jan; 14(1):33-40. PubMed ID: 7779261
[TBL] [Abstract][Full Text] [Related]
4. Conformation of the transmembrane domain of the epidermal growth factor receptor.
Brandt-Rauf PW; Monaco R; Pincus MR
J Protein Chem; 1994 Feb; 13(2):227-31. PubMed ID: 7914727
[TBL] [Abstract][Full Text] [Related]
5. Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene.
Bargmann CI; Weinberg RA
Proc Natl Acad Sci U S A; 1988 Aug; 85(15):5394-8. PubMed ID: 2899890
[TBL] [Abstract][Full Text] [Related]
6. Influence of a mutation in the transmembrane domain of the p185c-erbB2 oncogene-encoded protein studied by molecular dynamics simulations.
Garnier N; Genest D; Hebert E; Genest M
J Biomol Struct Dyn; 1994 Apr; 11(5):983-1002. PubMed ID: 7946067
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylation process induced by epidermal growth factor alters the oncogenic and cellular neu (NGL) gene products.
Kokai Y; Dobashi K; Weiner DB; Myers JN; Nowell PC; Greene MI
Proc Natl Acad Sci U S A; 1988 Aug; 85(15):5389-93. PubMed ID: 2899889
[TBL] [Abstract][Full Text] [Related]
8. p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity.
Stern DF; Heffernan PA; Weinberg RA
Mol Cell Biol; 1986 May; 6(5):1729-40. PubMed ID: 2878363
[TBL] [Abstract][Full Text] [Related]
9. Biochemical comparisons of the normal and oncogenic forms of insect cell-expressed neu tyrosine kinases.
Guy PM; Carraway KL; Cerione RA
J Biol Chem; 1992 Jul; 267(20):13851-6. PubMed ID: 1352772
[TBL] [Abstract][Full Text] [Related]
10. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185.
Bargmann CI; Hung MC; Weinberg RA
Cell; 1986 Jun; 45(5):649-57. PubMed ID: 2871941
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic activation of p185neu stimulates tyrosine phosphorylation in vivo.
Stern DF; Kamps MP; Cao H
Mol Cell Biol; 1988 Sep; 8(9):3969-73. PubMed ID: 2464744
[TBL] [Abstract][Full Text] [Related]
12. An extra cysteine proximal to the transmembrane domain induces differential cross-linking of p185neu and p185neu.
Cao H; Bangalore L; Dompé C; Bormann BJ; Stern DF
J Biol Chem; 1992 Oct; 267(28):20489-92. PubMed ID: 1356980
[TBL] [Abstract][Full Text] [Related]
13. A subdomain in the transmembrane domain is necessary for p185neu* activation.
Cao H; Bangalore L; Bormann BJ; Stern DF
EMBO J; 1992 Mar; 11(3):923-32. PubMed ID: 1347745
[TBL] [Abstract][Full Text] [Related]
14. Neu and its ligands: from an oncogene to neural factors.
Peles E; Yarden Y
Bioessays; 1993 Dec; 15(12):815-24. PubMed ID: 7908191
[TBL] [Abstract][Full Text] [Related]
15. Transmembrane domain sequence requirements for activation of the p185c-neu receptor tyrosine kinase.
Chen LI; Webster MK; Meyer AN; Donoghue DJ
J Cell Biol; 1997 May; 137(3):619-31. PubMed ID: 9151669
[TBL] [Abstract][Full Text] [Related]
16. Repression of neu-induced clonogenicity by dimethylsulfoxide correlates with decreased levels of neu-encoded cell-surface p185 and changes in phosphotyrosine content of endogenous proteins.
Matin A; Hung MC
Cancer Lett; 1993 Jan; 68(1):55-60. PubMed ID: 7678546
[TBL] [Abstract][Full Text] [Related]
17. The role of non-ras transforming genes in chemical carcinogenesis.
Cooper CS
Environ Health Perspect; 1991 Jun; 93():33-40. PubMed ID: 1685444
[TBL] [Abstract][Full Text] [Related]
18. neu protooncogene fused to an immunoglobulin heavy chain gene requires immunoglobulin light chain for cell surface expression and oncogenic transformation.
Flanagan JG; Leder P
Proc Natl Acad Sci U S A; 1988 Nov; 85(21):8057-61. PubMed ID: 2903500
[TBL] [Abstract][Full Text] [Related]
19. Specific short transmembrane sequences can inhibit transformation by the mutant neu growth factor receptor in vitro and in vivo.
Lofts FJ; Hurst HC; Sternberg MJ; Gullick WJ
Oncogene; 1993 Oct; 8(10):2813-20. PubMed ID: 8104327
[TBL] [Abstract][Full Text] [Related]
20. TPA inhibits the tyrosine kinase activity of the neu protein in vivo and in vitro.
Cao H; Decker S; Stern DF
Oncogene; 1991 May; 6(5):705-11. PubMed ID: 1675782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
